… drug development. Compared to developing a drug de novo, drug repositioning may
reduce the drug development period to 6.5 years and the cost for repositioning a drug is $300 …

… (Graph-based Prior Knowledge) for improving in silico drug repositioning via using the prior
… (2) We propose a multimodal framework that combines the prior knowledge with two types …

… not need prior knowledge, and the repositioned drugs are just … knowledge about the targets,
such as 3D protein structures, whereas knowledge-based methods require the knowledge …

… The authors used a Bayesian statistics approach to rank drug-disease relationships according
to prior knowledge. Then, they integrated ranked relationships with other biological entity …

… The technique does not require much prior knowledge about the action of the drug or the
pathology behind a phenotype; the creation of signatures from direct mRNA readout helps to …

… built networks corresponding to prior knowledge for use as … knowledge, can future indications
be predicted?’ may more closely reflect the problem being addressed in drug repositioning…

… The safety information in the drug labels is usually obtained in the clinical trial and augmented
with the observations in the post-market use of the drug. Therefore, our drug repositioning …

… As less prior knowledge about the known drug combinations is utilized, the accuracy of
unsupervised methods is always moderate. However, they can predict some new …

… drug repositioning based on the rational association between diseases and SEs. We
extracted 3,175 relationships between diseases and SEs. For some of the drug repositioning …

… target (C) in our LBD to focus on drug repositioning and adverse drug events. As casual
findings, we retrieved two groups of semantic predications in SemMedDB: a) having a drug as …